MRLB-223

MRLB-223 is a preferential HDAC1 and HDAC2 inhibitor with activity against tumor cells.MRLB-223 induces histone hyperacetylation, intrinsic apoptotic pathway activation, tumor cell apoptosis, Hsp90 hyperacetylation, and caspase-dependent Bcr-Abl degradation.MRLB-223 mediates p53-independent tumor cell death, with activity suppressed by Bcl-2 overexpression, and kills Bcr-Abl-expressing myeloid cells.MRLB-223 exerts effects in mice bearing Eμ-myc lymphomas.MRLB-223 can be used for the research of Eμ-myc lymphoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • CAS. Nr.: 937727-03-2
  • Formel: C23H23N5O3S
  • Molecular Weight:449.53
  • Speicherung:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biologische Aktivität
  • Chemical Information
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs

Alle HDAC Isoform-spezifische Produkte anzeigen

More

Alle Bcr-Abl Isoform-spezifische Produkte anzeigen

More

Alle HSP Isoform-spezifische Produkte anzeigen

More
100 mg

Angebot einholen Auf Lager

Please select quantity
Amount: USD 0.00